Cargando…

BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers worldwide and 30% of patients with CRC experience metastasis. Patients with metastatic colorectal cancer (mCRC) have a 5-year overall survival rate of <10%. V-raf murine sarcoma viral oncogene homolog B1 (BRAF) and V-Ki-ras2 Ki...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zi-Nan, Zhao, Lin, Yu, Li-Feng, Wei, Min-Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333923/ https://www.ncbi.nlm.nih.gov/pubmed/32665851 http://dx.doi.org/10.1093/gastro/goaa022

Ejemplares similares

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
por: Gattenlöhner, S., et al.
Publicado: (2009)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

BRAF-mutated metastatic colorectal cancer between past and future
por: Cremolini, Chiara, et al.
Publicado: (2015)

Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer
por: Ntavatzikos, Anastasios, et al.
Publicado: (2017)

Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma
por: Stefanius, Karoliina, et al.
Publicado: (2011)

Mitochondrial Respiration in KRAS and BRAF Mutated Colorectal Tumors and Polyps
por: Rebane-Klemm, Egle, et al.
Publicado: (2020)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
por: Bożyk, Aleksandra, et al.
Publicado: (2021)

Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations
por: Li, Wenbin, et al.
Publicado: (2015)

Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
por: Yokota, Tomoya
Publicado: (2012)

Sensitive High-Resolution Melting Analysis for Screening of KRAS and BRAF Mutations in Iranian Human Metastatic Colorectal Cancers
por: Niya, Mohammad Hadi Karbalaie, et al.
Publicado: (2016)

Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer
por: Franczak, Claire, et al.
Publicado: (2020)

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
por: Rosati, Gerardo, et al.
Publicado: (2021)

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
por: Modest, D. P., et al.
Publicado: (2016)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014)

KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
por: Garcia-Carbonero, Nuria, et al.
Publicado: (2020)

KRAS and BRAF mutations in serum exosomes from patients with colorectal cancer in a Chinese population
por: Hao, Yi-Xin, et al.
Publicado: (2017)

Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer
por: Popovici, Vlad, et al.
Publicado: (2013)

Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation
por: Huang, Chi-Jung, et al.
Publicado: (2016)

The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
por: Won, Daeyoun David, et al.
Publicado: (2017)

Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer
por: Gökmen, İvo, et al.
Publicado: (2023)

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
por: Yang, Qiwei, et al.
Publicado: (2018)

Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2009)

MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers
por: Choi, Yong Won, et al.
Publicado: (2016)

Clinicopathologic distribution of KRAS and BRAF mutations in a Chinese population with colorectal cancer precursor lesions
por: Yi, Chenghao, et al.
Publicado: (2016)

A Systematic Literature Review and Meta-Analysis Describing the Prevalence of KRAS, NRAS, and BRAF Gene Mutations in Metastatic Colorectal Cancer
por: Levin-Sparenberg, Elizabeth, et al.
Publicado: (2020)

Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR
por: Nagakubo, Yuki, et al.
Publicado: (2019)

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
por: Aasebø, Kristine, et al.
Publicado: (2020)

KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
por: Renaud, S, et al.
Publicado: (2015)

KRAS, p53 and BRAF Gene Mutations and Aneuploidy in Sporadic Colorectal Cancer Progression
por: Calistri, Daniele, et al.
Publicado: (2006)

Colorectal Cancer Prognosis Is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study
por: Lee, Joon-Hyop, et al.
Publicado: (2019)

KRAS/NRAS/BRAF Mutation Rate in Saudi Academic Hospital Patients With Colorectal Cancer
por: Saharti, Samah
Publicado: (2022)

Mutation patterns and prognostic analysis of BRAF/KRAS/PIK3CA in colorectal cancer
por: Wang, Chengfeng, et al.
Publicado: (2022)

High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE ‐ hypermutated colorectal cancers
por: Favre, Loetitia, et al.
Publicado: (2022)

BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer—A Case Series Study Target Therapy of BRAF-Mutated mCRC
por: Yeh, Jen-Hao, et al.
Publicado: (2021)

KRAS and BRAF Concomitant Mutations in a Patient with Metastatic Colon Adenocarcinoma: An Interesting Case Report
por: Cafiero, Concetta, et al.
Publicado: (2020)

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
por: Guedes, Joana G, et al.
Publicado: (2013)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort
por: Sorbye, Halfdan, et al.
Publicado: (2015)

The Role of BRAF in Metastatic Colorectal Carcinoma–Past, Present, and Future
por: Djanani, Angela, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3ucvtmpqcs3vpgvsh1euigicdv